In our previous article, we covered FDA new drug approvals for 2018. In the present article, we look at patent filings, litigation, regulatory and clinical data, related to these drug approvals, as a case study of fusing complementary data sources to provide comprehensive pharma competitive intelligence.
Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives.
The artificial intelligence (AI) landscape is growing quickly. Artificial intelligence startups raised $5B in 2016, a 10-fold increase since 2012. Tech giants (Google, Microsoft, IBM) are contributing heavily to this acceleration, both in academic and practical pursuits. Google published 218 papers on machine learning in 2016, nearly double the number of publications in 2014. In December 2016, Microsoft launched a new venture fund specifically to evaluate and fund AI startups, kicking off the fund with an investment in Element AI, then acquiring Maluuba just one month later.  
Patent prosecution analytics can provide valuable insight into the performance of an organization’s IP operations just as other forms of analytics help in reducing cost, in making better decisions and in creating new products and services. Technology companies who are actively filing patents can achieve cost savings and faster times to grant through prosecution analytics. I will illustrate what I mean by looking at two leading technology companies with different prosecution performance - Cisco and Juniper Network.